To carry out their activities, Research Teams of the Frédéric Joliot Institute for Life Sciences have developed high-profile technological platforms in many areas : biomedical imaging, structural biology, metabolomics, High-Throughput screening, level 3 microbiological safety laboratory...
All the news of the Institute of life sciences Frédéric Joliot
Institute | Diagnosis and innovative treatment | Mass spectrometry | Biomarkers
Medicines and Healthcare Technologies Department of the Frédéric Joliot Institute for Life Sciences, directed by Christophe Junot, carries out research in Diagnostic and Therapeutic Innovation, in particular in the Molecular Innovation area, around four thematic axes :
It is affiliated with two LabEx: the Laboratory of Excellence in Research on Medication and Innovative Therapeutics (LERMIT) and the Laboratory of Excellence in Chemistry of Multifunctional Molecular Architectures and Materials (CHARM3AT).
Researchers at SPI are proposing an innovative multiplexing method for rapid identification of several microbial isolates in a single mass spectrometry analysis. This approach opens up prospects for the large-scale identification of microorganisms resulting from culturomics programs.
Researchers from SCBM (DMTS) and SB2SM (I2BC) describe a novel and optimized approach to the total photoreduction of 13C-labelled CO2 to carbon monoxide (CO), and the immediate reuse of the latter for the synthesis of high value-added compounds. A step towards a radiochemistry of carbon isotopes potentially useful in human health.
In a study conducted by a team from the Marie Lannelongue Hospital, SPI researchers have established a difference between the metabolomic profiles of heart grafts harvested from pigs in a state of encephalic death or dead after controlled circulatory arrest. This work contributes to the exploration and validation of the use of hearts taken from people who have died after controlled circulatory arrest as a new source of grafts.
Researchers at SCBM have used a click-and-release chemistry approach to mass-release an anti-cancer drug into cells from cleavable nanomicelles, thanks to a bioorthogonal activation process. A step towards the development of new nanomedicines
Des chercheurs de l'institut montrent qu’une stratégie fondée sur la formation du radical anion CO2●- marqué au carbone 14 ou carbone 11 s’avère payante pour radiomarquer en conditions douces des médicaments.
A team from SIMoS and SCBM, in collaboration with researchers from I2BC, has shown that autophagic degradation is at work when mammalian cells are poisoned by ricin. Stimulating this process could provide additional protection against this deadly toxin.
Researchers at BioMaps (SHFJ) and SPI (DMTS) have studied the pharmacokinetics of a novel immuno-radioligand targeting the endothelin A receptor (ETA), overexpressed in many cancers, particularly glioblastoma. The immunoPET imaging approach used in this study in a preclinical model confirms the theranostic potential of this antibody.
To carry out their activities, researchers of Medicines and Healthcare Technologies Department have access to several research platforms, two of which certified
IBiSA, within the Frédéric Joliot Institute for Life Sciences:
CEA is a French government-funded technological research organisation in four main areas: low-carbon energies, defense and security, information technologies and health technologies. A prominent player in the European Research Area, it is involved in setting up collaborative projects with many partners around the world.